Table 2 |
||||||
|
Probability of meropenem and imipenem attaining pharmacodynamic targets over entire dosing interval for 30, 50, and 100 percent T>MIC for selected bacterial populations [42] |
||||||
|
Pharmacodynamic target for entire dosing interval |
||||||
|
|
||||||
|
30 percent T > MIC |
50 percent T > MIC |
100 percent T > MIC |
||||
|
|
|
|
||||
|
Species |
Meropenem |
Imipenem |
Meropenem |
Imipenem |
Meropenem |
Imipenem |
|
|
||||||
|
Escherichia coli |
100 |
100 |
100 |
100 |
100 |
94 |
|
Klebsiella pneumoniae |
100 |
100 |
99 |
100 |
99 |
91 |
|
Enterobacter cloacae |
100 |
100 |
100 |
100 |
95 |
71 |
|
Serratia marcescens |
99 |
99 |
99 |
99 |
97 |
57 |
|
Acinetobacter baumannii |
83 |
89 |
79 |
88 |
31 |
60 |
|
Pseudomonas aeruginosa |
93 |
92 |
87 |
87 |
47 |
27 |
|
|
||||||
|
T>MIC, time greater than minimum inhibitory concentration. |
||||||
|
Slama Critical Care 2008 12:233 doi:10.1186/cc6994 |
||||||